Apollomics, Inc. (NASDAQ:APLM) Short Interest Down 44.6% in June

Apollomics, Inc. (NASDAQ:APLM) saw a significant decline in short interest in June. As of June 15th, there was short interest totalling 80,200 shares, a decline of 44.6% from the May 31st total of 144,700 shares. Based on an average daily volume of 391,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are short sold.

Apollomics Stock Performance

Shares of NASDAQ:APLM opened at $0.21 on Friday. Apollomics has a 52-week low of $0.18 and a 52-week high of $6.20. The stock’s fifty day simple moving average is $0.31 and its 200-day simple moving average is $0.59.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their target price on Apollomics from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th.

Institutional Trading of Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC acquired a new stake in Apollomics, Inc. (NASDAQ:APLM) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned approximately 0.15% of Apollomics as of its most recent SEC filing. Hedge funds and other institutional investors own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.